Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
filingDate |
2020-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a55d622ebb4e9ccfe90cc8cd0bdb1b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc48e89cd858e800db2779c42d0256ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80e36d8f344099254d0014167e8a2d4f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a95b657a8ddc7eff2786b503d14e99de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0afba8fcabd6c979ea0bb3b642243003 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14617211f7de4e9768a3bbfdf292cdab |
publicationDate |
2021-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2021048280-A1 |
titleOfInvention |
Treatment of rms by switching therapy |
abstract |
The present invention relates to the anti-CD20 monoclonal antibody ofatumumab for use in the treatment or prevention of relapsing multiple sclerosis, wherein ofatumumab is used in a patient who has been treated with a disease-modifying therapy other than ofatumumab. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022219057-A1 |
priorityDate |
2019-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |